LEADER 03765nam  22006495  450 
001 9910254546603321
005 20200629144507.0
010   $a81-322-2607-0
024 7 $a10.1007/978-81-322-2607-9
035   $a(CKB)3710000000577138
035   $a(EBL)4354112
035   $a(SSID)ssj0001607073
035   $a(PQKBManifestationID)16315253
035   $a(PQKBTitleCode)TC0001607073
035   $a(PQKBWorkID)14897141
035   $a(PQKB)10151545
035   $a(DE-He213)978-81-322-2607-9
035   $a(MiAaPQ)EBC4354112
035   $a(PPN)191696455
035   $a(EXLCZ)993710000000577138
100   $a20160120d2016      u|             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aRadiopharmaceuticals for Therapy $b[electronic resource] /$fby F. F. (Russ) Knapp, Ashutosh Dash
205   $a1st ed. 2016.
210  1$aNew Delhi :$cSpringer India :$cImprint: Springer,$d2016.
215   $a1 online resource (357 p.)
300   $aDescription based upon print version of record.
311   $a81-322-2606-2 
320   $aIncludes bibliographical references.
330   $aThis book provides detailed information on therapeutic radiopharmaceuticals and discusses emerging technologies which have potential for broad clinical implementation.  Recent advances in molecular biology, radiopharmaceutical chemistry and radioisotope production have stimulated a new era for the use of radiopharmaceuticals for targeted radionuclide therapy (TRT). Emerging clinical trials include use of peptides and monoclonal antibodies radiolabeled with therapeutic radionuclides for cancer therapy.  In addition, small molecules are used for the treatment of chronic diseases such as metastatic bone pain palliation and radiation synovectomy of inflammatory joints. In the interventional arena, therapy of primary and metastatic liver cancer and arterial restenosis following angioplasty of both the coronary and peripheral arteries are being explored. Reactor and accelerator production of therapeutic radioisotopes is also integrated into these discussions. The development and use of radiopharmaceutical targeting characteristics required for treatment of specific disease processes and how these are implemented for radiopharmaceutical design strategies are also described. Radiopharmaceuticals for Therapy will benefit audiences in nuclear medicine and radionuclide therapy and will thus prove an invaluable source of up-to-date information for students, radiopharmaceutical scientists and professionals working in the radiopharmacy and nuclear medicine specialties.
606   $aNuclear medicine
606   $aPharmacotherapy
606   $aOncology  
606   $aEndocrinology 
606   $aNuclear Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H29048
606   $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aEndocrinology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33053
615  0$aNuclear medicine.
615  0$aPharmacotherapy.
615  0$aOncology  .
615  0$aEndocrinology .
615 14$aNuclear Medicine.
615 24$aPharmacotherapy.
615 24$aOncology.
615 24$aEndocrinology.
676   $a610
700   $aKnapp$b F. F. (Russ)$4aut$4http://id.loc.gov/vocabulary/relators/aut$01064980
702   $aDash$b Ashutosh$4aut$4http://id.loc.gov/vocabulary/relators/aut
906   $aBOOK
912   $a9910254546603321
996   $aRadiopharmaceuticals for Therapy$92542050
997   $aUNINA